Skip to main content

Advertisement

SpringerLink
Log in

Comparing RECIST with EORTC criteria in metastatic bladder cancer

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Objectives

To compare RECIST and EORTC criteria in an evaluation of response to therapy in metastatic bladder cancer and to assess their influence on decisions to administer additional therapy.

Materials and methods

A total of 42 untreated patients (38 male, 4 female) with metastatic bladder cancer were included in the study, which took place between July 2007 and April 2013. The mean age was 66.1 ± 9.93 years (range 41–84 years). A total of 144 metastatic foci were evaluated using multislice CT and 18FDG-PET/CT before and after first-line chemotherapy. The locations, sizes, numbers and SUVmax of the metastatic foci before and after chemotherapy were recorded, and the response to therapy was evaluated separately using RECIST and EORTC criteria, after which a statistical comparison was made.

Results

According to the RECIST and EORTC criteria, the rate of complete remission (CR) was 9.5 and 16.6 %, the rate of partial remission (PR) was 28.6 and 40.5 %, the rate of stable disease (SD) was 23.8 and 14.3 %, and the rate of progressive disease (PD) was 31.0 and 28.6 %, respectively. The overall response rate (ORR) was 38.1 versus 57.1 %, respectively, and there were no differences between the two criteria in terms of their detection of progressive disease. The rate of SD was higher with RECIST criteria; however, the difference between the two criteria was not significant in terms of PR and CR.

Conclusion

A group of patients that had been determined as having a SD according to RECIST criteria were grouped as PR and/or CR according to EORTC criteria. Additional chemotherapy protocols can be used in second-line chemotherapy and/or cisplatin-resistant patients, according to RECIST criteria. In evaluating the response to first-line chemotherapy for metastatic bladder cancer, EORTC criteria, using 18FDG-PET/CT scans, can be considered as a more applicable and accurate diagnostic tool. The anatomical findings obtained through imaging methods and from functional/metabolic data obtained by PET/CT can be useful in the planning of second- or third-line chemotherapy, and a high accuracy in re-staging can spare patients from second-line or even third-line chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI et al (2010) Clinical value of fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 28:3973–3978

    Article  PubMed  PubMed Central  Google Scholar 

  • Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181

    PubMed  CAS  Google Scholar 

  • Barentsz JO, Engelbrecht MR, Witjes JA et al (1999) MR imaging of the male pelvis. Eur Radiol 9(9):1722–1736

    Article  PubMed  CAS  Google Scholar 

  • Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P, Spanish Oncology Genitourinary Group (SOGUG) (2006) Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol 17:113–117

    Article  Google Scholar 

  • Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855 (Epub 2010 Mar 15)

    Article  PubMed  Google Scholar 

  • Bouchelouche K, Turkbey B, Choyke PL (2012) PET/CT and MRI in bladder cancer. J Cancer Sci Ther S14(1):7692. doi:10.4172/1948-5956.S14-001

    PubMed  Google Scholar 

  • Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L (2005) FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32:1412–1417

    Article  PubMed  CAS  Google Scholar 

  • El Fakhri G, Surti S, Trott CM et al (2011) Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med 52:347–353

    Article  PubMed  PubMed Central  Google Scholar 

  • Folio L, Derderian V, Steinberg SM, Turkbey E, Apolo AB (2014) Assessing tumor response using CT density-volume trajectory in metastatic bladder cancer. J Clin Oncol 32:5s (suppl; abstr 4539)

    Article  Google Scholar 

  • Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J et al (2010) Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 85(1):1–10. doi:10.1159/000318985 (Epub 2010 Jul 26)

    Article  PubMed  Google Scholar 

  • Jadvar H, Quan V, Henderson RW, Conti PS (2008) [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 13:42–47

    Article  PubMed  PubMed Central  Google Scholar 

  • Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B et al (2011) Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol 45:122–128

    Article  PubMed  Google Scholar 

  • Jones EC, Chezmar JL, Nelson RC, Bernardino ME (1992) The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol 158:535–539

    Article  PubMed  CAS  Google Scholar 

  • Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA et al (2009) Prospective study of 18F fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314–4320

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu IJ, Lai YH, Espiritu JI, Segall GM, Srinivas S et al (2006) Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int 77:69–75

    Article  PubMed  Google Scholar 

  • Lodde M, Lacombe L, Friede J, Morin F, Saourine A et al (2010) Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 106:658–663

    Article  PubMed  Google Scholar 

  • Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY et al (2012) Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81:2411–2416

    Article  PubMed  Google Scholar 

  • Mertens LS, Mir MC, Scott AM, Lee ST, Fioole-Bruining A, Vegt E et al (2014) 18F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 83(2):393–398. doi:10.1016/j.urology.2013.10.032

    Article  PubMed  Google Scholar 

  • Morisawa N, Koyama T, Togashi K (2006) Metastatic lymph nodes in urogenital cancers: contribution of imaging findings. Abdom Imaging 31:620–629

    Article  PubMed  CAS  Google Scholar 

  • Onishi H, Murakami T, Kim T, Hori M, Iannaccone R, Kuwabara M et al (2006) Hepatic metastases: detection with multi-detector row CT, SPIO-enhanced MR imaging, and both techniques combined. Radiology 239:131–138

    Article  PubMed  Google Scholar 

  • Pfannschmidt J, Bischoff M, Muley T et al (2008) Diagnosis of pulmonary metastases with helical CT: the effect of imaging techniques. Thorac Cardiovasc Surg 56:471–475

    Article  PubMed  CAS  Google Scholar 

  • Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27(3):289–293

    Article  PubMed  PubMed Central  Google Scholar 

  • Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939–949

    Article  PubMed  Google Scholar 

  • Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236

    Article  PubMed  Google Scholar 

  • Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    Article  PubMed  Google Scholar 

  • Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675

    PubMed  CAS  Google Scholar 

  • Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133(3):403–407

    PubMed  CAS  Google Scholar 

  • Sternberg CN, Pansadoro V, Calabrò F et al (2003) Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97(7):1644–1652

    Article  PubMed  Google Scholar 

  • Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I et al (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57:641–647

    Article  PubMed  Google Scholar 

  • Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T et al (2013) Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn J Clin Oncol 43(9):923–928. doi:10.1093/jjco/hyt096 (Epub 2013 Jul 25)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, School of Medicine, Sifa University, Izmir, Turkey

    Hakan Öztürk

  2. Basmane Hospital of Sifa University, Fevzipasa Boulevard No: 172/2, Basmane, 35240, Konak, Izmir, Turkey

    Hakan Öztürk

Authors
  1. Hakan Öztürk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Öztürk.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests. Financial support has not been received.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Öztürk, H. Comparing RECIST with EORTC criteria in metastatic bladder cancer. J Cancer Res Clin Oncol 142, 187–194 (2016). https://doi.org/10.1007/s00432-015-2022-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-2022-2

Keywords

Search

Navigation